Pharmacogenomic study, prospective, multicenter. Individualized treatment based on EGFR mutations and level of BRCA1 expression in patients with advanced lung adenocarcinoma
This is a pharmacogenic, prospective, and multicenter study in patients with advanced lung adenocarcinoma.